Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

주식 순위 #545
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
주가
$6.89
시가총액
$43.94B
변동 (1일)
-2.91%
변동 (1년)
-24.78%
국가
CN
거래 Jiangsu Hengrui Medicine Co., Ltd. (600276)

카테고리

Healthcare
Jiangsu Hengrui Medicine Co., Ltd. (600276)의 EPS
2026 기준 EPS TTM: 0
Jiangsu Hengrui Medicine Co., Ltd.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Jiangsu Hengrui Medicine Co., Ltd.의 EPS 기록 (2001 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2025 $0.17 24.16%
2024 $0.14 42.56%
2023 $0.10 8.71%
2022 $0.09 -20.86%
2021 $0.11 -27.04%
2020 $0.15 26.95%
2019 $0.12 29.68%
2018 $0.09 21.09%
2017 $0.08 29.95%
2016 $0.06 12.79%
2015 $0.05 35.40%
2014 $0.04 17.27%
2013 $0.03 20.88%
2012 $0.03 22.97%
2011 $0.02 21.98%
2010 $0.02 13.04%
2009 $0.02 62.63%
2008 $0.01 8.79%
2007 $0.01 116.67%
2006 0.00 61.54%
2005 0.00 36.84%
2004 0.00 26.67%
2003 0.00 25.00%
2002 0.00 -7.69%
2001 0.00 0.00%